ARTICLE | Company News
Vernalis, Novartis deal
January 5, 2015 8:00 AM UTC
Novartis terminated a 2004 deal granting the pharma exclusive, worldwide rights to IV AUY922 to treat cancer. Novartis discontinued the Phase II solid tumors candidate after a compound advancement ev...